Lactate Dehydrogenase 5 Isoenzyme Overexpression Defines Resistance of Prostate Cancer to Radiotherapy

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Apr 10

PMID 24714743

Citations 45

Authors

M I Koukourakis

A Giatromanolaki

M Panteliadou

S E Pouliliou

P S Chondrou

S Mavropoulou

E Sivridis

Affiliations

Soon will be listed here.

Abstract

Background: Radiotherapy provides high-cure rates in prostate cancer. Despite its overall slow clinical growth, high proliferation rates documented in a subset of tumours relate to poor radiotherapy outcome. This study examines the role of anaerobic metabolism in prostate cancer growth and resistance to radiotherapy.

Methods: Biopsy samples from 83 patients with prostate cancer undergoing radical hypofractionated and accelerated radiotherapy were analysed for MIB1 proliferation index and for lactate dehydrogenase isoenzyme LDH5, a marker of tumour anaerobic metabolism. Ninety-five surgical samples were in parallel analysed. Correlation with histopathological variables, PSA and radiotherapy outcome was assessed. Dose-response experiments were performed in PC3 and DU145 cancer cell lines.

Results: High MIB1 index (noted in 25% of cases) was directly related to Gleason score (P<0.0001), T3-stage (P=0.0008) and PSA levels (P=0.03). High LDH5 (noted in 65% of cases) was directly related to MIB1 index (P<0.0001), Gleason score (P=0.02) and T3-stage (P=0.001). High Gleason score, MIB1, LDH5 and PSA levels were significantly related to poor BRFS (P=0.007, 0.01, 0.03 and 0.01, respectively). High Gleason score (P=0.04), LDH5 (P=0.01) and PSA levels (P=0.003) were significantly related to local recurrence. MIB1 and T-stage did not affect local control. Silencing of LDHA gene in both prostate cancer cell lines resulted in significant radiosensitisation.

Conclusions: LDH5 overexpression is significantly linked to highly proliferating prostate carcinomas and with biochemical failure and local relapse following radiotherapy. Hypoxia and LDHA targeting agents may prove useful to overcome radioresistance in a subgroup of prostate carcinomas with anaerobic metabolic predilection.

Citing Articles

The metabolic role of lactate dehydrogenase in the growth of diffuse large B cell lymphoma.

Zhang J, Lu Q, Liu W, Zhou N Ann Hematol. 2024; 104(1):545-558.

PMID: 39500758 PMC: 11868233. DOI: 10.1007/s00277-024-06083-2.

Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects.

Tang X, Guo M, Zhang Y, Lv J, Gu C, Yang Y J Exp Clin Cancer Res. 2024; 43(1):216.

PMID: 39095902 PMC: 11297759. DOI: 10.1186/s13046-024-03136-2.

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer.

Al Saffar H, Chen D, Delgado C, Ingvar J, Hofman M, Lawrentschuk N Cancers (Basel). 2024; 16(5).

PMID: 38473301 PMC: 10931387. DOI: 10.3390/cancers16050939.

Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?.

Chetta P, Sriram R, Zadra G Cancers (Basel). 2023; 15(13).

PMID: 37444583 PMC: 10340474. DOI: 10.3390/cancers15133473.

HIF1α-dependent and independent pathways regulate the expression of PD-L1 in prostate cancer.

Xanthopoulou E, Kakouratos C, Nanos C, Gkegka A, Kalaitzis C, Giatromanolaki A Med Oncol. 2023; 40(5):151.

PMID: 37067635 PMC: 10110727. DOI: 10.1007/s12032-023-02017-6.

References

Abatzoglou I, Zois C, Pouliliou S, Koukourakis M . Establishment and validation of a method for multi-dose irradiation of cells in 96-well microplates. Biochem Biophys Res Commun. 2013; 431(3):456-9. DOI: 10.1016/j.bbrc.2012.12.146. View

Grossfeld G, Olumi A, Connolly J, Chew K, Gibney J, Bhargava V . Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol. 1998; 159(5):1437-43. DOI: 10.1097/00005392-199805000-00004. View

Palayoor S, Mitchell J, Cerna D, DeGraff W, John-Aryankalayil M, Coleman C . PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer. 2008; 123(10):2430-7. PMC: 4277812. DOI: 10.1002/ijc.23807. View

Yeoh E, Botten R, Butters J, Di Matteo A, Holloway R, Fowler J . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. 2010; 81(5):1271-8. DOI: 10.1016/j.ijrobp.2010.07.1984. View

Pierorazio P, Desai M, McCann T, Benson M, McKiernan J . The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome. BJU Int. 2008; 103(1):38-42. PMC: 5508732. DOI: 10.1111/j.1464-410X.2008.07952.x. View

Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C . Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2011; 13(1):43-54. DOI: 10.1016/S1470-2045(11)70293-5. View

Vesalainen S, Lipponen P, Talja M, Syrjanen K . Mitotic activity and prognosis in prostatic adenocarcinoma. Prostate. 1995; 26(2):80-6. DOI: 10.1002/pros.2990260204. View

Koukourakis M, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris A . Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology. 2009; 77(5):285-92. DOI: 10.1159/000259260. View

Koukourakis M, Papadopoulou A, Abatzoglou I, Panteliadou M, Sismanidou K, Touloupidis S . Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer. Anticancer Res. 2012; 32(10):4561-8. View

10.

Semenza G, Jiang B, Leung S, Passantino R, Concordet J, Maire P . Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996; 271(51):32529-37. DOI: 10.1074/jbc.271.51.32529. View

11.

Koukourakis M, Giatromanolaki A, Sivridis E, Gatter K, Trarbach T, Folprecht G . Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011; 17(14):4892-900. PMC: 3145151. DOI: 10.1158/1078-0432.CCR-10-2918. View

12.

Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V . Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol. 2008; 26(3):243-50. DOI: 10.1007/s00345-008-0257-0. View

13.

Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M . Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res. 2010; 16(5):1553-60. DOI: 10.1158/1078-0432.CCR-09-2546. View

14.

Hennessey D, Martin L, Atzberger A, Lynch T, Hollywood D, Marignol L . Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells. Urol Oncol. 2011; 31(7):1106-16. DOI: 10.1016/j.urolonc.2011.10.008. View

15.

Huang Y, Yu J, Yan C, Hou J, Pu J, Zhang G . Effect of small interfering RNA targeting hypoxia-inducible factor-1α on radiosensitivity of PC3 cell line. Urology. 2011; 79(3):744.e17-24. DOI: 10.1016/j.urology.2011.10.024. View

16.

Fowler J . The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005; 44(3):265-76. DOI: 10.1080/02841860410002824. View

17.

May M, Siegsmund M, Hammermann F, Loy V, Gunia S . Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol. 2007; 41(5):375-81. DOI: 10.1080/00365590701224445. View

18.

MARKERT C . Lactate dehydrogenase. Biochemistry and function of lactate dehydrogenase. Cell Biochem Funct. 1984; 2(3):131-4. DOI: 10.1002/cbf.290020302. View

19.

Galalae R, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R . Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 52(1):81-90. DOI: 10.1016/s0360-3016(01)01758-8. View

20.

Veltri R, Isharwal S, Miller M, Epstein J, Mangold L, Humphreys E . Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate. 2008; 68(16):1806-15. PMC: 2577716. DOI: 10.1002/pros.20848. View